SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Pazoo Inc (OTCMKTS:PZOO) confirmed that more than a week ahead of planned date, it has repaid the total of debt on its Convertible Promissory Note to firm Eastmore Capital LLC. It previously announced its plans to pay off the debt of Eastmore Capital in coming weeks. The stock reacted positive on the news. However, in last trading session, it eroded gains and declined more than 12% to close the trading session at $0.128.

The plans

Pazoo has been following an aggressive expansion and growth measures and intends to speed up the expansion plans in the coming period. In the future, the company may require financing debt to support the ongoing rapid expansion. The management is well informed about the impacts of dilution and, as shown in the debt paying initiatives, wants to protect the company’s shareholders. The company is of view that share valuations will demonstrate a stronger fundamental valuation gained through current site revenues, potential acquisitions, organic growth and new opportunities in the future.

The expert view

David Cunic, the CEO of Pazoo commented that raising funds to support growth and expansion plans is significant when it is accretive. The management has reduced the overhead to lowest levels to make sure every penny is directly invested into the growth and expansion of Pazoo and associated subsidiaries. There are several big opportunities available and the management intends on delivering on them.

The profile

Pazoo Inc (OTCMKTS:PZOO) is operational in the industry of health, wellness and safety. Its prime objective is to provide the best-in-class and advanced laboratory testing measures of cannabis and cannabinoids to save consumers from various forms of impurities, irregularities and contaminants. It has a wholly owned subsidiary unit known as Harris Lee and together with the firm and association with MA & Associates, it provides quality testing services. It has license to test cannabis in the state of Nevada.

SHARE
Previous articleTANARIS POWER HLDGS INC (OTCMKTS:TPHX) Updates On New Osprey Batteries
Next articleWhat’s The Buzz Surrounding Valmie Resources Inc (OTCBB:VMRI)?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.